The questions that take an hour elsewhere, answered in one click.
TheraRadar is a competitive intelligence platform for pharma and biotech. Search any drug, company, or target and get the answer with the live data behind it.
Questions TheraRadar answers
When does Keytruda’s patent expire?
Patent expiry dates, exclusivity windows, and biosimilar timelines from the Orange and Purple Books.
Open on TheraRadar →Any GLP-1 / obesity readouts coming up?
Search "obesity" or "GLP-1" in the filter box. Combine with sponsor (Lilly, Novo) for tighter cuts.
Open on TheraRadar →What’s reading out at AstraZeneca in the next 6 months?
Filter by sponsor → window: Next 6 months. Reveals their full near-term catalyst slate in one screen.
Open on TheraRadar →What drugs were approved this year?
Browse FDA approvals indexed by sponsor, indication, modality, and approval date.
Open on TheraRadar →What does the competitive landscape for IL-23 look like?
Approved drugs, pipeline assets, sponsors, and combination strategies for the IL-23 target.
Open on TheraRadar →What’s happening in cell & gene therapy?
CAR-T, AAV, CRISPR, and other CGT programs indexed by sponsor, modality, indication, and clinical phase.
Open on TheraRadar →Try any of these at theraradar.com →
Latest from TheraRadar Briefs
Long-form pharma intelligence, published weekly on TheraRadar.
Can IL-23 Drugs for Crohn's Start at Home?
Some Crohn's drugs already start with injections or a pill, but most IL-23 drugs still begin with clinic or hospital infusions. AbbVie wants to change that for Skyrizi, after its AFFIRM trial showed that starting with injections works.
Read on TheraRadar ↗Approved Early, Proven Later? What Happens to Cancer Accelerated Approvals
The FDA can put a cancer drug on the market years early, on the promise that proof will follow. We checked all 219 oncology accelerated approvals on the FDA's own lists to see how often a drug with accelerated approval goes on to get full approval.
Read on TheraRadar ↗How to Read a Cancer Trial and Tell If Patients Live Longer
A cancer drug 'works.' But did patients live longer, or did a tumor just shrink? The answer is which endpoint the trial made its primary measure. Here is how to read it.
Read on TheraRadar ↗The Daraxonrasib Success Story
How RAS went from "undruggable" to Rasonque, the first RAS-targeted medicine to extend survival in pancreatic cancer, and the best reporting and science behind it.
Read on TheraRadar ↗Can an IBD Biologic Last Six Months?
Several companies want to stretch IBD antibodies from a shot every few weeks to one every three months, or even six. Keeping the drug in the blood that long is the easy part. Whether the disease stays controlled right up to the next dose is the hard part, and the bet the newest programs are making.
Read on TheraRadar ↗Does Blocking IL-17F Actually Matter?
Two of the newest PsA drugs block IL-17F as well as IL-17A; the older ones block only IL-17A. A plain walk through what the extra target actually buys: clear help on the skin, no proven help on the joints yet, and a fungal cost in the middle.
Read on TheraRadar ↗Live data from public sources
Built on FDA approvals, ClinicalTrials.gov, SEC filings, and the Orange and Purple Books. Used by business development, competitive intelligence, medical affairs, and translational research teams across pharma and biotech.